ClinicalTrials.gg
Not yet recruitingNCT07074782NEUROPAUpdated May 6, 2026

Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues

An observational study in Glaucoma, sponsored by Association for Innovation and Biomedical Research on Light and Image. Not yet recruiting at 10 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Association for Innovation and Biomedical Research on Light and Image · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Glaucoma with a site in United Kingdom — 4 open to participants now, 5 under way, none of them phase 3. Glaucoma · United Kingdom.

Planned enrollment
Largest of 20
1,500 · median 100
Started
2026
with 1 other
Observational
20 of 48
2 open now
Registered
47th of 48
by date
Lead sponsor
2 of 48
Association for Innovation and Biomedical Research on Light and Image

Among the 48 studies in Glaucoma with a site in United Kingdom, this one has the largest planned enrollment of the 20 observational ones that give a count, is one of 2 that started in 2026, is one of 20 observational ones, and was the 47th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

4 of the 48 studies in Glaucoma with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Glaucoma with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate whether prostaglandin analogue eye drops have a direct neuroprotective effect on retinal ganglion cells - beyond their intraocular pressure (IOP)-lowering effect - in adult patients with glaucoma or ocular hypertension. The study includes individuals diagnosed with glaucoma (any sex/gender, adult age groups) undergoing standard clinical treatment. The main questions it aims to answer are:

  • Do prostaglandin analogues provide a neuroprotective effect on retinal ganglion cells that is independent of their IOP-lowering properties?
  • Should prostaglandin analogues be promoted/favoured over other IOP-lowering compounds for long-term glaucoma management?

Researchers will compare an interventional group, which consist of 750 eyes treated with prostaglandin analogues (e.g., latanoprost, travoprost, tafluprost, bimatoprost, unoprostone), with a control group, which consist of 750 eyes treated with non-prostaglandin IOP-lowering compounds (e.g., timolol, dorzolamide, brimonidine, netarsudil) to see if treatment with prostaglandin analogues is associated with better retinal ganglion cell survival over a period of 3 years (36 months).

Data will be collected from individuals who had at least 36 months of documented follow-up, with clinical data available at approximately 3, 6, 12, 24, and 36 months. Eligible individuals must have been treated with either prostaglandin analogues or other intraocular pressure (IOP)-lowering agents as part of routine clinical care. The data to be obtained from medical records will include at least:

  • Intraocular pressure readings
  • Visual field testing
  • OCT measures
  • Visual acuity
  • Adverse events
  • Treatment adherence/compliance
  • Additional glaucoma interventions
Read the detailed description

Glaucoma is among the most prevalent causes of irreversible blindness and is characterized by a progressive, irreversible degeneration of the retinal ganglion cells. Elevated intraocular pressure (IOP) is the most important glaucoma risk factor and the only risk factor that is readily modifiable with established treatment options, which include pharmacological approaches, laser treatment, and surgery. However, in many patients the disease progresses even after IOP is effectively lowered. Hence, neuroprotective treatment approaches that go beyond IOP lowering are needed.

Prostaglandin analogue eye drops reduce IOP by increasing uveoscleral outflow and are a well-established treatment option in ocular hypertension and glaucoma. Animal studies suggest that prostaglandin analogues may have a direct neuroprotective effect on retinal ganglion cells in addition to the effect mediated by IOP lowering. Proposed mechanisms of action include inhibiting of caspase-3 and cyclooxygenase as well as activation of polypeptide 2B1 and Klotho protein. However, this proposed additional, direct neuroprotective effect has not yet been tested in human patients. The viability and functional status of the retinal ganglion cells in glaucoma can be assessed by morphological readings, the standard nowadays being various optical coherence tomography modalities, and by visual field testing. Detection of Apoptosing Retinal Cells (DARC) is another, relatively novel technology that allows for quantification of retinal ganglion cell death, presumably on a much shorter time scale.

This is an observational, retrospective and longitudinal clinical study, according to the normal clinical practice.

This study aims to evaluate prostaglandin analogues neuroprotective effect on retinal ganglion cells apart from intraocular pressure (IOP)-lowering over a period of 3 years (36 months) and whether treatment of ocular hypertension and glaucoma participants with prostaglandin analogues should be promoted/ favoured over other IOP-lowering compounds. It will have a follow-up at 3, 6, 12, 24, and 36 months in eyes with glaucoma treated with prostaglandin analogues or a different topically applied compound.

03

Conditions studied

  • Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

1500 eyes (750 treated with prostaglandin analogues and 750 treated with a different IOP-lowering compound)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18+ years
  • Established glaucoma diagnosis (primary open-angle glaucoma, normal tension Glaucoma, pseudoexfoliation glaucoma, pigmentary dispersion glaucoma) in either eye
  • Visual field mean deviation (MD; location-weighted mean difference from average age-corrected visual field sensitivity) of 2 visual fields differing by no more than 3 dB, for a mean deviation of better than -6.0 dB, or by no more than 4 dB, for a mean deviation worse than -6.0 dB, as measured using Humphrey perimetry (or equivalent Haag-Streit / Octopus; in at least one eye; analogous to The United Kingdom Glaucoma Treatment Study)
  • Treatment with either prostaglandin analogues only or another topically applied IOP-lowering compound only for at least 3 years
  • Documented follow-up period of at least 3 years
  • At least 6 patient visits documented over the follow-up period with readings of IOP, visual field, OCT
  • No additional glaucoma intervention apart from laser trabeculoplasty and/or cataract surgery during the observational period

Exclusion criteria

Exclusion Criteria:

  • Follow-up period \< 3 years
  • Number of patient visits \<6 visits
  • Number of OCT, visual field readings during the observation period \< 6
  • Low compliance/therapy interruption
  • Beginning of combination therapy of prostaglandin analogues and other IOP lowering eye drops during the observation period
  • In case of glaucoma diagnosis in both eyes: different topical IOP-lowering treatment regimes (e.g. prostaglandin analogues in one eye and beta-adrenergic blocking agents in the fellow eye)
  • Additional glaucoma intervention during the observational period other than laser trabeculoplasty and/or cataract surgery
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Control Group (Non-Prostaglandin IOP-lowering compound)

    750 eyes treated with intraocular pressure-lowering compounds that do not belong to the prostaglandin analogue class. These treatments may include beta-adrenergic blocking agents (e.g., timolol, betaxolol), carbonic anhydrase inhibitors (e.g., dorzolamide, brinzolamide), alpha-2 adrenergic agonists (e.g., brimonidine) or rho kinase inhibitors (e.g., netarsudil).

  • Interventional group (prostaglandin analogues)

    750 eyes treated with any prostaglandin analogue, such as latanoprost (e.g., Xalatan® 50 µg/mL, Pfizer), travoprost, tafluprost, bimatoprost, or unoprostone.

06

What researchers measure

Primary outcomes

  1. Intraocular pressure (IOP), measured using a Goldmann applanation tonometer, an iCare tonometer, or similar. Change in IOP value (mmHg).

    Change in IOP value (mmHg).

    Time frame: 6 months

  2. Visual field (VF) - Mean Deviation, measured by automated perimetry testing devices, such as Haag-Streit Octopus, Zeiss Humphrey, or similar

    Evaluation of Change in Mean Deviation (MD, dB).

    Time frame: 6 months

  3. Visual Field - Pattern Standard Deviation, measured by automated perimetry testing devices, such as Haag-Streit Octopus, Zeiss Humphrey, or similar.

    Evaluation of Pattern Standard Deviation (PSD, dB).

    Time frame: 6 months

  4. Visual Field - Glaucoma Progression Analysis (GPA), measured by automated perimetry testing devices, such as Haag-Streit Octopus, Zeiss Humphrey, or similar.

    Evaluation of Glaucoma Progression Analysis (GPA, %/year).

    Time frame: 6 months

  5. Optical Coherence Tomography - Change in Average GCL+IPL Thickness, measured by Heidelberg Spectralis, Zeiss Cirrus, or similar.

    Evaluation of Change in Average GCL+IPL thickness (µm).

    Time frame: 6 months

  6. Optical Coherence Tomography - Average RNFL Thickness, measured by Heidelberg Spectralis, Zeiss Cirrus, or similar.

    Evaluation of average RNFL thickness (µm).

    Time frame: 6 months

  7. Optical Coherence Tomography - Disc Rim Area, measured by Heidelberg Spectralis, Zeiss Cirrus, or similar.

    Evaluation of Disc Rim Area (mm²).

    Time frame: 6 months

  8. Optical Coherence Tomography - Cup-to-disc Ratio, measured by Heidelberg Spectralis, Zeiss Cirrus, or similar.

    Evaluation of Cup-to-disc ratio (average and vertical).

    Time frame: 6 months

  9. Optical Coherence Tomography - Central Subfield Thickness, measured by Heidelberg Spectralis, Zeiss Cirrus, or similar.

    Evaluation of Central Subfield Thickness (µm).

    Time frame: 6 months

Secondary outcomes

  1. 10 Visual Acuity, measured by Best Corrected Visual Acuity (BCVA) score, using Snellen and/or LogMar charts.

    Changes in Best Corrected Visual Acuity (BCVA), Snellen and/or LogMar.

    Time frame: 6 months

  2. Adverse Events, as reported in patient's medical history.

    Reported blurred vision, conjunctival hyperemia, dryness, itching, irritation, pain, light sensitivity, eye lash growth, changes in iris colour, orbital fat atrophy/periorbitopathy, intraocular inflammation, macular oedema, vitreous floaters.

    Time frame: 6 months

  3. Adherence to Study Treatment

    Evaluation of number and percentage of participants adherence/compliance to study treatment (Yes or No).

    Time frame: 6 months

  4. Additional Glaucoma Interventions

    Evaluation of number and percentage of occurrence of additional glaucoma-related procedures during the follow-up period \[Laser trabeculoplasty and/or cataract surgery\].

    Time frame: 6 months

Other outcomes

  1. Retinal Cells apoptosis Detected by DARC Imaging

    Detection of Apoptosing Retinal Cells Cell Count

    Time frame: 6 months

  2. Vascular Outcomes - Change in the FAZ area (OCT-A parameter), measured by Zeiss Cirrus AngioPlex, or similar.

    Detection and quantification of Apoptosing Retinal Cells Cell Count (e.g., cells/mm²)

    Time frame: 6 months

  3. Vascular outcomes - Change in Peripapillary Vessel Density (OCT-A parameter), measured by Zeiss Cirrus AngioPlex, or similar.

    Evaluation of Peripapillary Vessel Density (%).

    Time frame: 6 months

  4. Vascular outcomes - Change in Macular Vessel Density (OCT-A parameter), measured by Zeiss Cirrus AngioPlex, or similar

    Evaluation of Macular Vessel Density (mm-1).

    Time frame: 6 months

  5. Vascular outcomes - Change in perfusion density (OCT-A parameter), measured by Zeiss Cirrus AngioPlex, or similar.

    Evaluation of perfusion density (a.u.).

    Time frame: 6 months

07

Study locations

10 sites
  • Department of Ophthalmology University of Bonn
    Bonn, Germany
    • Karl Mercieca · Contact
  • University Eye Hospital Leipzig
    Leipzig, Germany
    • Jan Darius Unterlauff · Contact
  • Centre for Clinical Trials at San Paolo Hospital University of Milan
    Milan, Italy
    • Luca Rossetti · Contact
  • Eye Unit, University Hospital Maggiore della Carità
    Novara, Italy
    • Alessandro Rabiolo · Contact
  • Centro de Oftalmologia Barraquer
    Barcelona, Spain
  • Retina Unit, Department of Ophthalmology, Bellvitge University Hospital
    Barcelona, Spain
    • Silvia S Moreno · Contact
  • University Hospital Basel
    Basel, Switzerland
    • Tim J Enz · Contact
  • Clinical Eye Research Centre - St. Paul's Eye Unit, Royal Liverpool University Hospital
    Liverpool, United Kingdom
  • ICORG - Imperial College Ophthalmologic Research Group
    London, United Kingdom
    • Eduardo Normando · Contact
  • NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, NHS Foundation Trust
    London, United Kingdom
    • HARI JAYARAM · Contact
08

References and documents

Publications

  • Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017 Nov 11;390(10108):2183-2193. doi: 10.1016/S0140-6736(17)31469-1. Epub 2017 May 31. PubMed 28577860 ↗
  • Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z; EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007 Nov;114(11):1965-72. doi: 10.1016/j.ophtha.2007.03.016. Epub 2007 Jul 12. PubMed 17628686 ↗
  • Peters D, Bengtsson B, Heijl A. Lifetime risk of blindness in open-angle glaucoma. Am J Ophthalmol. 2013 Oct;156(4):724-30. doi: 10.1016/j.ajo.2013.05.027. Epub 2013 Aug 7. PubMed 23932216 ↗
  • Chang EE, Goldberg JL. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology. 2012 May;119(5):979-86. doi: 10.1016/j.ophtha.2011.11.003. Epub 2012 Feb 18. PubMed 22349567 ↗
  • Lee HP, Tsung TH, Tsai YC, Chen YH, Lu DW. Glaucoma: Current and New Therapeutic Approaches. Biomedicines. 2024 Sep 3;12(9):2000. doi: 10.3390/biomedicines12092000. PubMed 39335514 ↗
  • Yamamoto K, Sato K, Yukita M, Yasuda M, Omodaka K, Ryu M, Fujita K, Nishiguchi KM, Machida S, Nakazawa T. The neuroprotective effect of latanoprost acts via klotho-mediated suppression of calpain activation after optic nerve transection. J Neurochem. 2017 Feb;140(3):495-508. doi: 10.1111/jnc.13902. Epub 2016 Dec 27. PubMed 27859240 ↗
  • Yamagishi R, Aihara M, Araie M. Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. Exp Eye Res. 2011 Sep;93(3):265-70. doi: 10.1016/j.exer.2011.06.022. Epub 2011 Jul 26. PubMed 21791206 ↗
  • Kanamori A, Naka M, Fukuda M, Nakamura M, Negi A. Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Exp Eye Res. 2009 Mar;88(3):535-41. doi: 10.1016/j.exer.2008.11.012. Epub 2008 Dec 3. PubMed 19084521 ↗
  • Nakanishi Y, Nakamura M, Mukuno H, Kanamori A, Seigel GM, Negi A. Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase. Exp Eye Res. 2006 Nov;83(5):1108-17. doi: 10.1016/j.exer.2006.05.018. Epub 2006 Jul 12. PubMed 16839545 ↗
  • Kudo H, Nakazawa T, Shimura M, Takahashi H, Fuse N, Kashiwagi K, Tamai M. Neuroprotective effect of latanoprost on rat retinal ganglion cells. Graefes Arch Clin Exp Ophthalmol. 2006 Aug;244(8):1003-9. doi: 10.1007/s00417-005-0215-0. Epub 2006 Jan 13. PubMed 16411104 ↗
  • Drago F, Valzelli S, Emmi I, Marino A, Scalia CC, Marino V. Latanoprost exerts neuroprotective activity in vitro and in vivo. Exp Eye Res. 2001 Apr;72(4):479-86. doi: 10.1006/exer.2000.0975. PubMed 11273675 ↗
  • Harper MM, Boese EA, Kardon RH, Ledolter J, Kuehn MH. High Correlation between Glaucoma Treatment with Topical Prostaglandin Analogs and BDNF Immunoreactivity in Human Retina. Curr Eye Res. 2021 May;46(5):739-745. doi: 10.1080/02713683.2020.1822417. Epub 2020 Sep 27. PubMed 32985274 ↗
  • Wagner IV, Stewart MW, Dorairaj SK. Updates on the Diagnosis and Management of Glaucoma. Mayo Clin Proc Innov Qual Outcomes. 2022 Nov 16;6(6):618-635. doi: 10.1016/j.mayocpiqo.2022.09.007. eCollection 2022 Dec. PubMed 36405987 ↗
  • Hill D, Choi S, Cordeiro MF. In Vivo Detection of Retinal Ganglion Cell Stress in Rodents with DARC. Methods Mol Biol. 2023;2708:123-129. doi: 10.1007/978-1-0716-3409-7_13. PubMed 37558966 ↗
  • Cordeiro MF, Hill D, Patel R, Corazza P, Maddison J, Younis S. Detecting retinal cell stress and apoptosis with DARC: Progression from lab to clinic. Prog Retin Eye Res. 2022 Jan;86:100976. doi: 10.1016/j.preteyeres.2021.100976. Epub 2021 Jun 5. PubMed 34102318 ↗
  • Yap TE, Donna P, Almonte MT, Cordeiro MF. Real-Time Imaging of Retinal Ganglion Cell Apoptosis. Cells. 2018 Jun 15;7(6):60. doi: 10.3390/cells7060060. PubMed 29914056 ↗
  • Stein JD, Khawaja AP, Weizer JS. Glaucoma in Adults-Screening, Diagnosis, and Management: A Review. JAMA. 2021 Jan 12;325(2):164-174. doi: 10.1001/jama.2020.21899. PubMed 33433580 ↗
  • Tan JC, Peters DM, Kaufman PL. Recent developments in understanding the pathophysiology of elevated intraocular pressure. Curr Opin Ophthalmol. 2006 Apr;17(2):168-74. doi: 10.1097/01.icu.0000193079.55240.18. PubMed 16552252 ↗
  • Conlon R, Saheb H, Ahmed II. Glaucoma treatment trends: a review. Can J Ophthalmol. 2017 Feb;52(1):114-124. doi: 10.1016/j.jcjo.2016.07.013. Epub 2016 Nov 17. PubMed 28237137 ↗
  • Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005 Apr 1;62(7):691-9. doi: 10.1093/ajhp/62.7.691. PubMed 15790795 ↗
  • Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995 Dec;113(12):1514-7. doi: 10.1001/archopht.1995.01100120044006. PubMed 7487618 ↗
  • Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1(SUPPL1):S107-20. doi: 10.1016/j.survophthal.2008.08.010. PubMed 19038618 ↗
  • Chen JY, Le A, Caprioli J, Giaconi JA, Nouri-Mahdavi K, Law SK, Bonelli L, Coleman AL, Demer JL. Orbital Fat Volume After Treatment with Topical Prostaglandin Agonists. Invest Ophthalmol Vis Sci. 2020 May 11;61(5):46. doi: 10.1167/iovs.61.5.46. PubMed 32455434 ↗
  • Goh AS, Nassiri N, Kohn JC, Rootman DB, Giaconi J, Law SK, Coleman AL, Caprioli J, Goldberg RA. Prostaglandin Eyedrops Are Associated With Decreased Thicknesses of Eyelid Dermis and Orbicularis Oculi Muscle: Ultrasonographic Findings. Ophthalmic Plast Reconstr Surg. 2016 Sep-Oct;32(5):337-41. doi: 10.1097/IOP.0000000000000535. PubMed 26237530 ↗
  • Impagnatiello F, Bastia E, Almirante N, Brambilla S, Duquesroix B, Kothe AC, Bergamini MVW. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. Br J Pharmacol. 2019 Apr;176(8):1079-1089. doi: 10.1111/bph.14328. Epub 2018 May 24. PubMed 29669171 ↗
  • Sakata R, Shirato S, Miyata K, Aihara M. Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution. Eye (Lond). 2014 Dec;28(12):1446-51. doi: 10.1038/eye.2014.224. Epub 2014 Sep 19. PubMed 25233818 ↗
  • Sakata R, Shirato S, Miyata K, Aihara M. Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. Jpn J Ophthalmol. 2014 Mar;58(2):212-7. doi: 10.1007/s10384-013-0299-8. Epub 2014 Jan 7. PubMed 24390604 ↗
  • Fung TY, Iyaswamy A, Sreenivasmurthy SG, Krishnamoorthi S, Guan XJ, Zhu Z, Su CF, Liu J, Kan Y, Zhang Y, Wong HLX, Li M. Klotho an Autophagy Stimulator as a Potential Therapeutic Target for Alzheimer's Disease: A Review. Biomedicines. 2022 Mar 18;10(3):705. doi: 10.3390/biomedicines10030705. PubMed 35327507 ↗
  • Dong Q, Ding Y, Zhou Y, Zhao X, Hu L, Zhang Z, Xu X. Low-level expression of Cmyc in mature neurons: Maintaining neuronal function and preventing neurodegeneration. Neural Regen Res. 2026 Jun 1;21(6):2523-2530. doi: 10.4103/NRR.NRR-D-24-01367. Epub 2025 Apr 29. PubMed 40313104 ↗
  • Kang JM, Tanna AP. Glaucoma. Med Clin North Am. 2021 May;105(3):493-510. doi: 10.1016/j.mcna.2021.01.004. Epub 2021 Apr 2. PubMed 33926643 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Jun 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 20, 2025
StartEst.
May 2026
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07074782
Lead sponsor
Association for Innovation and Biomedical Research on Light and Image
Collaborators
European Vision Institute Clinical Research Network
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
May 2026 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
May 6, 2026

Study contacts

Ana S Silva, PhD
Contact
neuropa@aibili.pt
+351239480112
Liliana C Soares, MsC
Contact
lcarvalho@aibili.pt
+351239480105

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion